Current Data

U.S. Cannabis Spot Index up 1.4% to $1,147 per pound.

The simple average (non-volume weighted) price increased by $16 to $1,294 per pound, with 68% of transactions (one standard deviation) in the $515 to $2,074 per pound range. The average reported deal size declined to 4.1 pounds from 4.2 pounds last week. In grams, the Spot price was $2.53, and the simple average price was $2.85.

The relative frequency of trades for indoor flower grew this week, by 1%, while that for greenhouse product decreased by the same proportion. The relative frequency of transactions for outdoor flower was unchanged compared to last week. Warehouse-grown flower’s share of the total reported weight moved nationwide increased by over 2% this week, while the relative volume of outdoor product contracted by the same proportion. The relative volume of greenhouse flower was stable week-over-week.  

The U.S. Spot Index rose for the second straight week, by 1.4%, to settle at $1,147 per pound. This week’s national composite price is the highest observed since early in H2 – in the week ending July 13th, specifically – and is up by 9.6%, or $100, from the current annual trough documented in the week ending November 9th. Still, as we close in on the end of 2018, this week’s U.S. Spot rate is off by nearly 20% year-over-year, compared to the national composite price of $1,431 per pound reported for the week ending December 22, 2017. This week’s uptick in the U.S. Spot was due largely to rising supply side rates in California and Colorado. Perhaps the most notable state-level price movement – the increase that took place in Massachusetts – had a minimal effect on the overall national average.

The national volume-weighted price for flower to be sold in adult-use markets slipped slightly this week. Declines in California’s adult-use sector, as well as in Oregon, Nevada, and Alaska, outweighed small increases in Colorado and Washington. Increases in wholesale rates in the medical portion of California’s market, as well as in Michigan, Massachusetts, and Illinois, were primarily responsible for pushing up the national price for product designated for registered patients.